Navigation Links
Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
Date:3/1/2011

SAN DIEGO, March 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Citi 2011 Global Health Care Conference on Thursday, March 3, 2011 at 10:00 a.m. Eastern Time at the Hilton New York Hotel in New York City.
  • Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011 at 4:45 p.m. Eastern Time at The Boston Marriott Copley Place in Boston.

  • (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

    Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of these presentations will be available at the same location for 30 days following the meeting.

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com. ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale CommunicationsJason I. Spark, Senior Vice President619-849-6005
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
    2. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    3. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
    4. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
    5. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
    6. Optimer Pharmaceuticals Announces Key Additions to Management Team
    7. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
    8. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
    9. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
    10. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
    11. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/18/2017)... and Markets has announced the addition of the "Contraceptives - Global ... ... US, Canada , Japan , ... America , and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
    (Date:2/17/2017)... According to a new market research report ... Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End User (Healthcare ... the market is expected to reach USD 330.6 Million by 2021 ... from 2016 to 2021. Continue Reading ... ...
    (Date:2/17/2017)... Research and Markets has announced the addition of ... to their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
    Breaking Medicine Technology:
    (Date:2/18/2017)... PA (PRWEB) , ... February 17, 2017 , ... Butler ... about the Stannah Stairlift and other Butler products. Ken was impressed with the ... and agreed to endorse the product on his show. This endorsement by Ken ...
    (Date:2/18/2017)... ... February 18, 2017 , ... A ... information and contact points to easily connect elderly veterans of America's armed forces ... elder-care funding. It also conveys material on this year's increase in the Veterans ...
    (Date:2/17/2017)... ... February 17, 2017 , ... Wells ... the electronic prescribing of controlled and non-controlled substances plus the ability to manage ... in the United States now accept electronic prescriptions, according to the Office of ...
    (Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & Preventive ... FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... and preventive action (PA)? , The methods share techniques and tools but they ...
    (Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue ... that Karen Pilley has been promoted to Chief Executive Officer. , The ... paradigm – a shift that demands the transition from pay-for-service to pay-for-performance models. ...
    Breaking Medicine News(10 mins):